How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ceftriaxone-azithromycin-amoxicilline-clavulanate-clarithromycin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin (Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotics and macrolide antibiotics. Area: Infectious Disease.

phase 3 Beta-lactam antibiotics and macrolide antibiotics Bacterial cell wall (penicillin-binding proteins) and bacterial ribosome (50S subunit) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin (Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin) — Bayer. This is a combination of four beta-lactam and macrolide antibiotics that work by inhibiting bacterial cell wall synthesis and protein synthesis to kill or inhibit growth of susceptible bacteria.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin TARGET	Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin	Bayer	phase 3	Beta-lactam antibiotics and macrolide antibiotics	Bacterial cell wall (penicillin-binding proteins) and bacterial ribosome (50S subunit)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotics and macrolide antibiotics class)

Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin — Competitive Intelligence Brief. https://druglandscape.com/ci/ceftriaxone-azithromycin-amoxicilline-clavulanate-clarithromycin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab